GLAND PHARMA
Back to Balance Sheet
|
GLAND PHARMA Last 5 Year Total Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Liabilities | ₹12,449 Cr | ₹11,173 Cr | ₹10,611 Cr | ₹8,778 Cr | ₹7,834 Cr |
What is the latest Total Liabilities ratio of GLAND PHARMA ?
| Year | Total Liabilities |
|---|---|
| Mar2026 | ₹12,449 Cr |
| Mar2025 | ₹11,173 Cr |
| Mar2024 | ₹10,611 Cr |
| Mar2023 | ₹8,778 Cr |
| Mar2022 | ₹7,834 Cr |
How is Total Liabilities of GLAND PHARMA Trending?
| Years | Total Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹12,449 Cr | 11.42 | |
| Mar2025 | ₹11,173 Cr | 5.30 | |
| Mar2024 | ₹10,611 Cr | 20.89 | |
| Mar2023 | ₹8,778 Cr | 12.05 | |
| Mar2022 | ₹7,834 Cr | - | |
Compare Total Liabilities of peers of GLAND PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLAND PHARMA | ₹41,322.6 Cr | 3.2% | 2.4% | 24.7% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹477,312.0 Cr | 0.8% | 6.3% | 18.2% | Stock Analytics | |
| DIVIS LABORATORIES | ₹213,879.0 Cr | 8.6% | 20.7% | 18.5% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹194,094.0 Cr | 1.7% | 9.4% | 38.5% | Stock Analytics | |
| CIPLA | ₹118,993.0 Cr | 4.5% | 1.2% | -1.4% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹95,787.4 Cr | -0.3% | -14.8% | -9.5% | Stock Analytics | |
GLAND PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLAND PHARMA | 3.2% |
2.4% |
24.7% |
| SENSEX | 2.7% |
1.5% |
-5.6% |
You may also like the below Video Courses